Intrauterine injection of ovine interferon-tau alters oestrogen receptor and oxytocin receptor expression in the endometrium of cyclic ewes.
Intrauterine injection of ovine interferon-tau alters oestrogen receptor and oxytocin receptor expression in the endometrium of cyclic ewes.
复制标题
宫内注射绵羊干扰素-tau 会改变周期性母羊子宫内膜中雌激素受体和催产素受体的表达。
DOI：
--
复制
发表时间：
1995
影响因子：
3.5
通讯作者：
F. Bazer
中科院分区：
文献类型：
--
作者：
T. E. Spencer;N H Ing;T. L. Ott;J S Mayes;W. Becker;G. H. Watson;M. Mirando;F. Bazer
本研究确定了重组羊干扰素-tau（roIFN-tau; 2 × 10（7）抗病毒单位/天）或对照蛋白（6 mg/天）从发情后第11天至第14天（即第0天）宫内注射对周期性母羊中雌激素、孕酮和催产素受体的子宫内膜表达的影响。与对照蛋白相比，接受roIFN-tau的母羊在第15天的孕酮血浆浓度更高（P < 0.02，处理x天）。与接受对照蛋白质的母羊相比，注射roIFN-tau的母羊在第15天具有较低的子宫内膜水平或雌激素受体mRNA（P > 0.10）和蛋白质（P < 0.01）。原位杂交分析表明，雌激素受体mRNA更丰富的管腔和腺上皮的控制母羊相比，roIFN-tau治疗的母羊。免疫反应性雌激素受体也存在于管腔和腺上皮的控制，但不是roIFN-tau治疗的母羊。对照组和roIFN-tau处理组母羊子宫内膜孕酮受体mRNA和蛋白水平无显著差异（P > 0.10）。原位杂交分析表明，孕激素受体mRNA丰度低，在子宫内膜上皮和基质的控制和roIFN-tau注射母羊。免疫反应性孕激素受体存在于子宫内膜基质和上皮的控制母羊，但仅限于roIFN-tau治疗的母羊的基质。注射roIFN-tau的母羊子宫内膜中催产素受体密度低于对照蛋白质（P < 0.01）;然而，催产素受体亲和力不受处理影响（P > 0.10）。浓度的13，14-二氢-15-酮前列腺素F2 a（PGFM）没有增加外源性催产素管理在控制和roIFN-tau治疗的母羊在发情后第10天或第12天。然而，在第14天，对照母羊对催产素有反应，PGFM的血浆浓度增加，而接受roIFN-tau的母羊对催产素仍无反应。这些结果表明，IFN-τ的抗黄体溶解作用是防止子宫内膜雌激素受体mRNA和蛋白质以及催产素受体密度的增加，这在母体识别妊娠期间消除了前列腺素F2 a的子宫释放。IFN-tau可能通过转录或转录后调节机制抑制雌激素受体mRNA的合成，从而抑制绵羊妊娠早期催产素受体的形成。
This study determined the effects of intrauterine injections of recombinant ovine interferon-tau; (roIFN-tau; 2 x 10(7) antiviral units/day) or control proteins (6 mg/day) from day 11 to day 14 post-oestrus = day 0) on endometrial expression of receptors fro oestrogen, progesterone and oxytocin in cyclic ewes. Plasma concentrations of progesterone were greater on day 15 in ewes receiving roIFN-tau compared with control proteins (P < 0.02, treatment x day). Ewes injected with roIFN-tau had lower endometrial levels or oestrogen receptor mRNA (P > 0.10) and protein (P < 0.01) on day 15 compared with ewes receiving control proteins. In situ hybridization analysis indicated that oestrogen receptor mRNA was more abundant in the luminal and glandular epithelium of control ewes compared with roIFN-tau-treated ewes. Immunoreactive oestrogen receptor was also present in the luminal and glandular epithelium of control, but not roIFN-tau-treated ewes. Endometrial levels of progesterone receptor mRNA and protein were not different (P > 0.10) between control and roIFN-tau-treated ewes. In situ hybridization analyses indicated that progesterone receptor mRNA abundance was low in endometrial epithelium and stroma of both control and roIFN-tau-injected ewes. Immunoreactive progesterone receptors were present in the endometrial stroma and epithelium of control ewes, but confined to the stroma of roIFN-tau-treated ewes. Oxytocin receptor density was lower (P < 0.01) in the endometrium of ewes injected with roIFN-tau than control proteins; however, oxytocin receptor affinity was not affected (P > 0.10) by treatment. Concentrations of 13,14-dihydro-15-ketoprostaglandin F2a (PGFM) were not increased by exogenous oxytocin administration in control and roIFN-tau-treated ewes on days 10 or 12 post-oestrus. However, on day 14, control ewes responded to oxytocin with increased plasma concentrations of PGFM, whereas ewes receiving roIFN-tau remained unresponsive to oxytocin. These results indicate that the an tiluteolytic effects of IFN-tau are to prevent increases in endometrial oestrogen receptor MRNA and protein and oxytocin receptor density which abrogates uterine release of prostaglandin F2a during maternal recognition of pregnancy. IFN-tau may inhibit the synthesis of oestrogen receptor mRNA by a transcriptional or post-transcriptional regulatory mechanism to suppress oxytocin receptor formation during early pregnancy in ewes.